251 related articles for article (PubMed ID: 24650865)
21. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
22. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
Fears R; Kaufmann S; Ter Meulen V; Zumla A;
Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
[TBL] [Abstract][Full Text] [Related]
23. A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.
Forson A; Kwara A; Kudzawu S; Omari M; Otu J; Gehre F; de Jong B; Antonio M
BMC Infect Dis; 2018 Apr; 18(1):149. PubMed ID: 29606091
[TBL] [Abstract][Full Text] [Related]
24. Previous treatment in predicting drug-resistant tuberculosis in an area bordering East London, UK.
Melzer M; Gupta N; Petersen I; Cook S; Hall B
Int J Infect Dis; 2010 Aug; 14(8):e717-22. PubMed ID: 20542460
[TBL] [Abstract][Full Text] [Related]
25. Tuberculosis in Poland in 2016.
Korzeniewska-Koseła M
Przegl Epidemiol; 2018; 72(2):189-205. PubMed ID: 30111079
[TBL] [Abstract][Full Text] [Related]
26. Drug-resistance pattern of Mycobacterium tuberculosis strains from patients with pulmonary and extrapulmonary tuberculosis during 2006 to 2013 in a Korean tertiary medical center.
Lee HY; Lee J; Lee YS; Kim MY; Lee HK; Lee YM; Shin JH; Ko Y
Korean J Intern Med; 2015 May; 30(3):325-34. PubMed ID: 25995663
[TBL] [Abstract][Full Text] [Related]
27. [Frequency of drug resistant tuberculosis in Poland in 2000 as compared to 1997].
Augustynowicz-Kopeć E; Zwolska Z; Jaworski A; Kostrzewa E; Klatt M; Swiderska A; Drozd I
Pneumonol Alergol Pol; 2002; 70(3-4):193-202. PubMed ID: 12271966
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999-2018).
Camphor HS; Viney K; Polkinghorne B; Pennington K
Commun Dis Intell (2018); 2020 Aug; 44():. PubMed ID: 32829704
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
[TBL] [Abstract][Full Text] [Related]
31. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
[TBL] [Abstract][Full Text] [Related]
32. The effect of migration within the European Union/European Economic Area on the distribution of tuberculosis, 2007 to 2013.
Hollo V; Kotila SM; Ködmön C; Zucs P; van der Werf MJ
Euro Surveill; 2016; 21(12):. PubMed ID: 27035746
[TBL] [Abstract][Full Text] [Related]
33. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.
Ulmasova DJ; Uzakova G; Tillyashayhov MN; Turaev L; van Gemert W; Hoffmann H; Zignol M; Kremer K; Gombogaram T; Gadoev J; du Cros P; Muslimova N; Jalolov A; Dadu A; de Colombani P; Telnov O; Slizkiy A; Kholikulov B; Dara M; Falzon D
Euro Surveill; 2013 Oct; 18(42):. PubMed ID: 24176581
[TBL] [Abstract][Full Text] [Related]
34. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting.
Vella V; Racalbuto V; Guerra R; Marra C; Moll A; Mhlanga Z; Maluleke M; Mhlope H; Margot B; Friedland G; Shah NS; Gandhi NR
Int J Tuberc Lung Dis; 2011 Sep; 15(9):1170-5, i. PubMed ID: 21943840
[TBL] [Abstract][Full Text] [Related]
35. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
[TBL] [Abstract][Full Text] [Related]
36. Multidrug-resistant tuberculosis in Bangladesh: results from a sentinel surveillance system.
Banu S; Rahman MT; Ahmed S; Khatun R; Ferdous SS; Hosen B; Rahman MM; Ahmed T; Cavanaugh JS; Heffelfinger JD
Int J Tuberc Lung Dis; 2017 Jan; 21(1):12-17. PubMed ID: 28157459
[TBL] [Abstract][Full Text] [Related]
37. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Balabanova Y; Ignatyeva O; Fiebig L; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F
Thorax; 2016 Sep; 71(9):854-61. PubMed ID: 27012887
[TBL] [Abstract][Full Text] [Related]
38. Clinical profile of drug resistant tuberculosis in children.
Shah I; Chilkar S
Indian Pediatr; 2012 Sep; 49(9):741-4. PubMed ID: 22728624
[TBL] [Abstract][Full Text] [Related]
39. [Drug resistant tuberculosis].
Zwolska Z; Augustynowicz-Kopeć E
Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
[TBL] [Abstract][Full Text] [Related]
40. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation.
Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A
Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
